Cardioprotective effects of melatonin against myocardial injuries induced by chronic intermittent hypoxia in rats

Journal of Pineal Research

Volumn 58, Issue 1, 2015, Pages 12-25

  Yeung, Hang Mee ^a   Hung, Ming Wai ^a   Lau, Chi Fai ^a   Fung, Man Lung ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

calcium; intermittent hypoxia; ischemia reperfusion; melatonin; oxidative stress; sarcoplasmic reticulum; sleep apnea

Indexed keywords

CALCIUM ION; CYCLOOXYGENASE 2; INTERLEUKIN 6; LACTATE DEHYDROGENASE; MALONALDEHYDE; MANGANESE SUPEROXIDE DISMUTASE; MELATONIN; PROTEIN P22; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; ANTIOXIDANTS; BIOLOGICAL MARKERS; CARDIOTONIC AGENTS; CYTOKINES;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CALCIUM HOMEOSTASIS; CHRONIC INTERMITTENT HYPOXIA; CONTROLLED STUDY; HEART MUSCLE FIBROSIS; HEART MUSCLE INJURY; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; MALE; NONHUMAN; OXIDATIVE STRESS; PROPHYLAXIS; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; SARCOPLASMIC RETICULUM; SLEEP DISORDERED BREATHING; SYSTOLIC BLOOD PRESSURE; ANIMALS; ANOXIA; BIOSYNTHESIS; CHRONIC DISEASE; COMPLICATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; HEART DISEASES; METABOLISM; MYOCARDIUM; PATHOLOGY; RATS; SLEEP APNEA, OBSTRUCTIVE;

ANIMALS; ANOXIA; ANTIOXIDANTS; BIOLOGICAL MARKERS; CARDIOTONIC AGENTS; CHRONIC DISEASE; CYTOKINES; GENE EXPRESSION REGULATION; HEART DISEASES; MALE; MELATONIN; MYOCARDIUM; RATS; SLEEP APNEA, OBSTRUCTIVE; TRANSFORMING GROWTH FACTOR BETA;

EID: 84919663655     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12190     Document Type: Article

References (71)

1. Levy P, Ryan S, Oldenburg O, et al. Sleep apnoea and the heart. Eur Respir Rev 2013; 22: 333-352.
2. Kasai T,. Sleep apnea and heart failure. J Cardiol 2012; 60: 78-85.
3. Baguet JP, Barone-Rochette G, Tamisier R, et al. Mechanisms of cardiac dysfunction in obstructive sleep apnea. Nat Rev Cardiol 2012; 9: 679-688.
4. Chen L, Zhang J, Gan TX, et al. Left ventricular dysfunction and associated cellular injury in rats exposed to chronic intermittent hypoxia. J Appl Physiol 2008; 104: 218-223.
5. Ryan S, Taylor CT, McNicholas WT,. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 2005; 112: 2660-2667.
6. Yokoe T, Minoguchi K, Matsuo H, et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003; 107: 1129-1134.
7. Akasaka Y, Morimoto N, Ishikawa Y, et al. Myocardial apoptosis associated with the expression of proinflammatory cytokines during the course of myocardial infarction. Mod Pathol 2006; 19: 588-598.
8. Cinquegrana G, D'aniello L, Landi M, et al. Effects of different degrees of sympathetic antagonism on cytokine network in patients with ischemic dilated cardiomyopathy. J Card Fail 2005; 11: 213-219.
9. Dai RP, Dheen ST, He BP, et al. Differential expression of cytokines in the rat heart in response to sustained volume overload. Eur J Heart Fail 2004; 6: 693-703.
10. Ye Y, Martinez JD, Perez-Polo RJ, et al. The role of eNOS, iNOS, and NF-kappaB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin. Am J Physiol Heart Circ Physiol 2008; 295: H343-H351.
11. Birnbaum Y, Ye Y, Rosanio S, et al. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc Res 2005; 65: 345-355.
12. Sakata Y, Chancey AL, Divakaran VG, et al. Transforming growth factor-beta receptor antagonism attenuates myocardial fibrosis in mice with cardiac-restricted overexpression of tumor necrosis factor. Basic Res Cardiol 2008; 103: 60-68.
13. Li Y, Wu J, He Q, et al. Angiotensin (1-7) prevent heart dysfunction and left ventricular remodeling caused by renal dysfunction in 5/6 nephrectomy mice. Hypertens Res 2009; 32: 369-374.
14. Fielitz J, Hein S, Mitrovic V, et al. Activation of the cardiac renin-angiotensin system and increased myocardial collagen expression in human aortic valve disease. J Am Coll Cardiol 2001; 37: 1443-1449.
15. Vinten-Johansen J,. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 2004; 61: 481-497.
16. Yeung HM, Kravtsov GM, Ng KM, et al. Chronic intermittent hypoxia alters Ca2+ handling in rat cardiomyocytes by augmented Na+/Ca2+ exchange and ryanodine receptor activities in ischemia-reperfusion. Am J Physiol Cell Physiol 2007; 292: C2046-C2056.
17. Chen L, Zhang J, Hu X, et al. The Na+/Ca2+ exchanger-1 mediates left ventricular dysfunction in mice with chronic intermittent hypoxia. J Appl Physiol 2010; 109: 1675-1685.
18. Reiken S, Gaburjakova M, Guatimosim S, et al. Protein kinase A phosphorylation of the cardiac calcium release channel (ryanodine receptor) in normal and failing hearts. Role of phosphatases and response to isoproterenol. J Biol Chem 2003; 278: 444-453.
19. Netticadan T, Temsah R, Osada M, et al. Status of Ca2+/calmodulin protein kinase phosphorylation of cardiac SR proteins in ischemia-reperfusion. Am J Physiol 1999; 277: C384-C391.
20. Brunner F, Andrew P, Wolkart G, et al. Myocardial contractile function and heart rate in mice with myocyte-specific overexpression of endothelial nitric oxide synthase. Circulation 2001; 104: 3097-3102.
21. Tong X, Ying J, Pimentel DR, et al. High glucose oxidizes SERCA cysteine-674 and prevents inhibition by nitric oxide of smooth muscle cell migration. J Mol Cell Cardiol 2008; 44: 361-369.
22. Garcia JJ, Lopez-Pingarron L, Almeida-Souza P, et al. Protective effects of melatonin in reducing oxidative stress and in preserving the fluidity of biological membranes: a review. J Pineal Res 2014; 56: 225-237.
23. Mauriz JL, Collado PS, Veneroso C, et al. A review of the molecular aspects of melatonin's anti-inflammatory actions: recent insights and new perspectives. J Pineal Res 2013; 54: 1-14.
24. Galano A, Tan DX, Reiter RJ,. On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK. J Pineal Res 2013; 54: 245-257.
25. Yu L, Sun Y, Cheng L, et al. Melatonin receptor-mediated protection against myocardial ischemia/reperfusion injury: role of SIRT1. J Pineal Res 2014; 57: 228-238.
26. Zhang H, Liu D, Wang X, et al. Melatonin improved rat cardiac mitochondria and survival rate in septic heart injury. J Pineal Res 2013; 55: 1-6.
27. Yang Y, Duan W, Jin Z, et al. JAK2/STAT3 activation by melatonin attenuates the mitochondrial oxidative damage induced by myocardial ischemia/reperfusion injury. J Pineal Res 2013; 55: 275-286.
28. Tan DX, Manchester LC, Reiter RJ, et al. Ischemia/reperfusion-induced arrhythmias in the isolated rat heart: prevention by melatonin. J Pineal Res 1998; 25: 184-191.
29. Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P,. The role of melatonin in acute myocardial infarction. Front Biosci 2012; 17: 2433-2441.
30. Andrabi SA, Sayeed I, Siemen D, et al. Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti-apoptotic effects of melatonin. FASEB J 2004; 18: 869-871.
31. Hung MW, Kravtsov GM, Lau CF, et al. Melatonin ameliorates endothelial dysfunction, vascular inflammation, and systemic hypertension in rats with chronic intermittent hypoxia. J Pineal Res 2013; 55: 247-256.
32. Hanf R, Drubaix I, Marotte F, et al. Rat cardiac hypertrophy. Altered sodium-calcium exchange activity in sarcolemmal vesicles. FEBS Lett 1988; 236: 145-149.
33. Belaidi E, Joyeux-Faure M, Ribuot C, et al. Major role for hypoxia inducible factor-1 and the endothelin system in promoting myocardial infarction and hypertension in an animal model of obstructive sleep apnea. J Am Coll Cardiol 2009; 53: 1309-1317.
34. Troncoso Brindeiro CM, Da Silva AQ, Allahdadi KJ, et al. Reactive oxygen species contribute to sleep apnea-induced hypertension in rats. Am J Physiol Heart Circ Physiol 2007; 293: H2971-H2976.
35. Akasaki T, Ohya Y, Kuroda J, et al. Increased expression of gp91phox homologues of NAD(P)H oxidase in the aortic media during chronic hypertension: involvement of the renin-angiotensin system. Hypertens Res 2006; 29: 813-820.
36. Oudot A, Martin C, Busseuil D, et al. NADPH oxidases are in part responsible for increased cardiovascular superoxide production during aging. Free Radic Biol Med 2006; 40: 2214-2222.
37. Kusaka I, Kusaka G, Zhou C, et al. Role of AT1 receptors and NAD(P)H oxidase in diabetes-aggravated ischemic brain injury. Am J Physiol Heart Circ Physiol 2004; 286: H2442-H2451.
38. Isabelle M, Vergeade A, Moritz F, et al. NADPH oxidase inhibition prevents cocaine-induced up-regulation of xanthine oxidoreductase and cardiac dysfunction. J Mol Cell Cardiol 2007; 42: 326-332.
39. Krijnen PA, Meischl C, Hack CE, et al. Increased Nox2 expression in human cardiomyocytes after acute myocardial infarction. J Clin Pathol 2003; 56: 194-199.
40. Zhang P, Hou M, Li Y, et al. NADPH oxidase contributes to coronary endothelial dysfunction in the failing heart. Am J Physiol Heart Circ Physiol 2009; 296: H840-H846.
41. Park YM, Park MY, Suh YL, et al. NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats. Biochem Biophys Res Commun 2004; 313: 812-817.
42. Hayashi T, Yamashita C, Matsumoto C, et al. Role of gp91phox-containing NADPH oxidase in left ventricular remodeling induced by intermittent hypoxic stress. Am J Physiol Heart Circ Physiol 2008; 294: H2197-H2203.
43. Elkareh J, Kennedy DJ, Yashaswi B, et al. Marinobufagenin stimulates fibroblast collagen production and causes fibrosis in experimental uremic cardiomyopathy. Hypertension 2007; 49: 215-224.
44. Calderone A, Murphy RJ, Lavoie J, et al. TGF-beta(1) and prepro-ANP mRNAs are differentially regulated in exercise-induced cardiac hypertrophy. J Appl Physiol 2001; 91: 771-776.
45. Bonizzi G, Piette J, Schoonbroodt S, et al. Reactive oxygen intermediate-dependent NF-kappaB activation by interleukin-1beta requires 5-lipoxygenase or NADPH oxidase activity. Mol Cell Biol 1999; 19: 1950-1960.
46. Clark RA,. Valente, AJ Nuclear factor kappa B activation by NADPH oxidases. Mech Ageing Dev 2004; 125: 799-810.
47. Hasper D, Hummel M, Kleber FX, et al. Systemic inflammation in patients with heart failure. Eur Heart J 1998; 19: 761-765.
48. Niebauer J, Clark AL, Webb-Peploe KM, et al. Exercise training in chronic heart failure: effects on pro-inflammatory markers. Eur J Heart Fail 2005; 7: 189-193.
49. Lapointe MC, Isenovic E,. Interleukin-1beta regulation of inducible nitric oxide synthase and cyclooxygenase-2 involves the p42/44 and p38 MAPK signaling pathways in cardiac myocytes. Hypertension 1999; 33: 276-282.
50. Mendez M, Lapointe MC,. PPARgamma inhibition of cyclooxygenase-2, PGE2 synthase, and inducible nitric oxide synthase in cardiac myocytes. Hypertension 2003; 42: 844-850.
51. Yang X, Ma N, Szabolcs MJ, et al. Upregulation of COX-2 during cardiac allograft rejection. Circulation 2000; 101: 430-438.
52. Kurada BR, Li LC, Mulherkar N, et al. MADD, a splice variant of IG20, is indispensable for MAPK activation and protection against apoptosis upon tumor necrosis factor-alpha treatment. J Biol Chem 2009; 284: 13533-13541.
53. Li Q, Guo Y, Tan W, et al. Cardioprotection afforded by inducible nitric oxide synthase gene therapy is mediated by cyclooxygenase-2 via a nuclear factor-kappaB dependent pathway. Circulation 2007; 116: 1577-1584.
54. De Oliveira-Marques V, Cyrne L, Marinho HS, et al. A quantitative study of NF-kappaB activation by H2O2: relevance in inflammation and synergy with TNF-alpha. J Immunol 2007; 178: 3893-3902.
55. Huang NL, Chiang SH, Hsueh CH, et al. Metformin inhibits TNF-alpha-induced IkappaB kinase phosphorylation, IkappaB-alpha degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation. Int J Cardiol 2009; 134: 169-175.
56. Wu KK,. Control of cyclooxygenase-2 transcriptional activation by pro-inflammatory mediators. Prostaglandins Leukot Essent Fatty Acids 2005; 72: 89-93.
57. Simko F, Pechanova O,. Potential roles of melatonin and chronotherapy among the new trends in hypertension treatment. J Pineal Res 2009; 47: 127-133.
58. Ersahin M, Sehirli O, Toklu HZ, et al. Melatonin improves cardiovascular function and ameliorates renal, cardiac and cerebral damage in rats with renovascular hypertension. J Pineal Res 2009; 47: 97-106.
59. Bertuglia S, Reiter RJ,. Melatonin reduces ventricular arrhythmias and preserves capillary perfusion during ischemia-reperfusion events in cardiomyopathic hamsters. J Pineal Res 2007; 42: 55-63.
60. Veneroso C, Tunon MJ, Gonzalez-Gallego J, et al. Melatonin reduces cardiac inflammatory injury induced by acute exercise. J Pineal Res 2009; 47: 184-191.
61. Simko F, Pechanova O, Pelouch V, et al. Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodelling in spontaneously hypertensive rats. J Hypertens 2009; 27 (Suppl 6): S5-S10.
62. Nava M, Quiroz Y, Vaziri N, et al. Melatonin reduces renal interstitial inflammation and improves hypertension in spontaneously hypertensive rats. Am J Physiol Renal Physiol 2003; 284: F447-F454.
63. Zhou J, Zhang S, Zhao X, et al. Melatonin impairs NADPH oxidase assembly and decreases superoxide anion production in microglia exposed to amyloid-beta1-42. J Pineal Res 2008; 45: 157-165.
64. Kevin LG, Camara AK, Riess ML, et al. Ischemic preconditioning alters real-time measure of O2 radicals in intact hearts with ischemia and reperfusion. Am J Physiol Heart Circ Physiol 2003; 284: H566-H574.
65. Zweier JL, Wang P, Kuppusamy P,. Direct measurement of nitric oxide generation in the ischemic heart using electron paramagnetic resonance spectroscopy. J Biol Chem 1995; 270: 304-307.
66. Szarszoi O, Asemu G, Vanecek J, et al. Effects of melatonin on ischemia and reperfusion injury of the rat heart. Cardiovasc Drugs Ther 2001; 15: 251-257.
67. Sahna E, Olmez E, Acet A,. Effects of physiological and pharmacological concentrations of melatonin on ischemia-reperfusion arrhythmias in rats: can the incidence of sudden cardiac death be reduced? J Pineal Res 2002; 32: 194-198.
68. Xie Y, Zhu Y, Zhu WZ, et al. Role of dual-site phospholamban phosphorylation in intermittent hypoxia-induced cardioprotection against ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2005; 288: H2594-H2602.
69. Maclennan DH, Abu-Abed M, Kang C,. Structure-function relationships in Ca(2+) cycling proteins. J Mol Cell Cardiol 2002; 34: 897-918.
70. Ying J, Tong X, Pimentel DR, et al. Cysteine-674 of the sarco/endoplasmic reticulum calcium ATPase is required for the inhibition of cell migration by nitric oxide. Arterioscler Thromb Vasc Biol 2007; 27: 783-790.
71. Cohen RA, Adachi T,. Nitric-oxide-induced vasodilatation: regulation by physiologic s-glutathiolation and pathologic oxidation of the sarcoplasmic endoplasmic reticulum calcium ATPase. Trends Cardiovasc Med 2006; 16: 109-114.